BPC-157 may be worth exploring for: Men recovering from tendon, ligament, or muscle injuries Those experiencing chronic joint pain or inflammation Men on TRT who train intensely and want additional recovery support Individuals with gastrointestinal issues (gut inflammation, leaky gut, NSAID damage) Those interested in peptide therapy as part of a comprehensive wellness protocol Who Should Avoid BPC-157 Anyone with active cancer (BPC-157s angiogenic properties could theoretically promote tumor blood supply) Individuals allergic to any component of the peptide formulation Those unwilling to undergo medical supervision Anyone expecting BPC-157 to replace testosterone therapy for hypogonadism References Sikiric P, Seiwerth S, Rucman R, et al
In this study the mice used, have been reported to be deficient in endogenous melatonin production, as are C57BL/6 mice, but importantly are still able to express canonical melatonin receptors (28, 42)
Tissue sections were incubated with primary antibodies (4-HNE, abcam, #ab46545, 1:5000, rabbit and CCR2, abcam, ab273050, 1:200, rabbit) diluted in 1% BSA in PBS and incubated at 4 C overnight
Delivery method: Injectable (subcutaneous)
